End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004

AIDS

Volumn 21, Issue 18, 2007, Pages 2435-2443

  Lucas, Gregory M ^a,b,e   Mehta, Shruti H ^b   Atta, Mohamed G ^a   Kirk, Gregory D ^a,b   Galai, Noya ^b,d   Vlahov, David ^b,c   Moore, Richard D ^a,b  

^a SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d UNIVERSITY OF HAIFA   (Israel)

^e NONE   (United States)

Author keywords

Antiretroviral therapy; Chronic kidney disease; Cohort study; End stage renal disease; HIV infection; Renal replacement therapy

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AFRICAN AMERICANS; AIDS-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; EPIDEMIOLOGIC METHODS; FEMALE; HIV SERONEGATIVITY; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RENAL REPLACEMENT THERAPY; SOCIOECONOMIC FACTORS;

EID: 36349027007     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32827038ad     Document Type: Article

References (34)

1. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Diseases and Kidney Diseases; 2005. http://www.usrds.org. Accessed August 2006.
2. Coresh J, Jaar B. Further trends in the etiology of end-stage renal disease in African-Americans. Curr Opin Nephrol Hypertens 1997; 6:243-249.
3. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2005, Vol. 17. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006. http://www.cdc.gov/ hiv/topics/surveillance/resources/reports. Accessed August 2006.
4. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
5. Atta MG, Choi MJ, Longenecker JC, Haymart M,WuJ, Nagajothi N, et al. Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy. Am J Med 2005; 118:1288.
6. Eggers PW, Kimmel PL. Is there an epidemic of HIV Infection in the US ESRD program? J Am Soc Nephrol 2004; 15:2477-2485.
7. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13:1933-1942.
8. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005; 161:999-1012.
9. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998; 352:783-784.
10. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, Heald AE, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002; 57:336-341.
11. Atta MG, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, et al. Antiretroviral therapy in the treatment of HIVassociated nephropathy. Nephrol Dial Transplant 2006; 21:2809-2813.
12. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546.
13. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817.
14. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
15. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960.
16. Cheng JT, Anderson HL Jr, Markowitz GS, Appel GB, Pogue VA, D'Agati VD. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 1999; 10:1566-1574.
17. Dettmeyer R, Wessling B, Madea B. Heroin associated nephropathy: a postmortem study. Forensic Sci Int 1998; 20:109-116.
18. Norris KC, Thornhill-Joynes M, Robinson C, Strickland T, Alperson BL, Witana SC, et al. Cocaine use, hypertension, and end-stage renal disease. Am J Kidney Dis 2001; 38:523-528.
19. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr 1998; 17 (suppl. 1):S38-S41.
20. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, et al. The ALIVE study, a longitudinal study of HIV infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
21. United States Renal Data System. Researcher's Guide to the USRDS Database. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006. http://www.usrds.org. Accessed August 2006.
22. Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR 1992; 41:1-19.
23. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
24. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195-202.
25. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61:1-6.
26. Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int 2006; 69:2243-2250.
27. Agaba EI, Agaba PA, Sirisena ND, Anteyi EA, Idoko JA. Renal disease in the acquired immunodeficiency syndrome in north central Nigeria. Niger J Med 2003; 12:120-125.
28. Kimmel PL, Umana WO, Bosch JP. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol 1993; 39:17-21.
29. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, Gooze L, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39:1199-1206.
30. Gardner LI, Holmberg SD, Williamson JM, Szczech LA, Carpenter CC, Rompalo AM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:203-209.
31. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIVR end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-2420.
32. Dettmeyer RB, Preuss J, Wollersen H, Madea B. Heroina-ssociated nephropathy. Expert Opin Drug Saf 2005; 4:19-28.
33. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial 2002; 15:162-171.
34. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585.